(1R,3s,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane

We are (1R,3s,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane CAS:423165-07-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name:
(1R,3s,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane
Synonym: (1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane; Intermediate of Maraviroc
Cas No.: 423165-07-5
Formula: C₁₃H₂₂N₄
MW: 234.34
EINECS No.: 1533716-785-6

HS Code: 2933990099 

UN No.: N.A
Hazard class: Non-dangerous goods
 
Specification

Items of Analysis	Standard of Analysis	Test Results
Appearance	White or similar white powder	Conforms
Purity (HPLC)	≥99%	99.75%
Single Impurity	≤1.0%	0.07%
Total impurities	≤1.0%	0.25%
Loss on drying	≤0.5%	0.12%
Residue on Ignition	≤0.15%	0.13%
Conclusion	Conforms to Factory Standard

 
 
Application
Intermediate of Maraviroc.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 




Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.cis-Anethol CAS:104-46-1 API and raw material are often confused due to the similar usage of the two terms.1692-25-7 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.6-etil-3-oxa-6-azaoctanol CAS:140-82-9 Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content.